Interim Results from a Phase 1 Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors.

Interim Results from a Phase 1 Trial of SL-801, a Novel XPO-1 Inhibitor, in…

by srs_admin

Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in…

November 16, 2017

Stemline Therapeutics Reports Third Quarter 2017 Financial Results November 9,…

November 9, 2017

Phase 2 trial of SL-701, a novel immunotherapy comprised of synthetic short peptides against GBM targets

Phase 2 trial of SL-701, a novel immunotherapy comprised of synthetic short…

by srs_admin

Stemline Announces Four SL-401 Presentations at Upcoming ASH Meeting November…

November 1, 2017

October 31, 2017 Stemline Therapeutics Update Call   VIEW PRESENTATION

October 31, 2017

Stemline Therapeutics Announces that Pivotal Trial of SL-401 in Blastic…

October 31, 2017

October 12, 2017 Corporate Presentation – October 2017   VIEW……

October 12, 2017

September 26, 2017 Ladenburg Thalmann 2017 Healthcare Conference   LISTEN…

September 26, 2017

September 25, 2017 Cantor Fitzgerald Global Healthcare Conference   LISTEN…

September 25, 2017